Posted by Michael Wonder on 11 May 2023
Insulin companies, PBMs pass the blame as they face bipartisan ire on pricing
10 May 2023 - Major stakeholders in the pharmaceutical industry on Wednesday testified in front of a key Senate panel to address questions over the affordability of insulin, with the assembled witnesses, as expected, passing the blame amongst each other.
Leaders from top insulin manufacturers Eli Lilly, Novo Nordisk and Sanofi joined with executives from top pharmacy benefit management companies CVS Health, Express Scripts and OptumRx to face the grilling from lawmakers on the Senate Committee on Health, Education, Labor and Pensions (HELP).
